Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference
September 11 2020 - 7:30AM
Business Wire
Oragenics, Inc. (NYSE American: OGEN), a
biopharmaceutical company dedicated to the development and
commercialization of a vaccine candidate to combat the novel
coronavirus pandemic (commonly referred to as COVID-19) today
announces that Alan Joslyn, Ph.D., President and Chief Executive
Officer, is scheduled to present at the H.C. Wainwright 22nd Annual
Global Investment Conference (the “Conference”). The Conference is
to be held virtually on September 14–16, 2020, and Dr. Joslyn is
scheduled to present on Wednesday, September 16, 2020 at 11:00 AM
ET.
A live webcast of Dr. Joslyn’s presentation will be available
through H.C. Wainwright’s virtual conference portal, located here,
and the presentation will be archived on the Oragenics website at
https://www.oragenics.com.
In addition, Dr. Joslyn will be available for virtual one-on-one
meetings from September 14–16, 2020. To schedule a meeting with Dr.
Joslyn, please contact the Conference coordinator at
meetings@hcwco.com.
About Oragenics, Inc.
Oragenics, Inc. is focused on the creation of the Terra CoV-2
vaccine candidate to combat the novel coronavirus pandemic and the
further development of effective treatments for novel antibiotics
against infectious disease. Oragenics is dedicated to the
development and commercialization of a vaccine candidate providing
specific immunity from novel coronavirus. The Terra CoV-2
immunization leverages coronavirus spike protein research conducted
by the National Institute of Health. In addition, Oragenics also
has an exclusive worldwide channel collaboration with ILH Holdings,
Inc. (n/k/a Eleszto Genetika, Inc.) relating to the development of
novel lantibiotics.
For more information about Oragenics, please visit
www.oragenics.com.
Safe Harbor Statement
Under the Private Securities Litigation Reform Act of 1995: This
release includes forward-looking statements that reflect
management’s current views with respect to future events and
performance. These forward-looking statements are based on
management’s beliefs and assumptions and information currently
available. The words “believe,” “expect,” “anticipate,” “intend,”
“estimate,” “project” and similar expressions that do not relate
solely to historical matters identify forward-looking statements.
Investors should be cautious in relying on forward-looking
statements because they are subject to a variety of risks,
uncertainties, and other factors that could cause actual results to
differ materially from those expressed in any such forward-looking
statements. These factors include, but are not limited to, the
following: the Company’s ability to advance the development of
TerraCoV2 under the timelines and in accord with the milestones it
projects; the Company’s ability to obtain funding for the
development of Noachis Terra’s TerraCoV2 vaccine, whether through
its own cash on hand, a grant from BARDA, or another alternative
source; the regulatory application process, research and
development stages, and future clinical data and analysis relating
to TerraCoV2, including any decisions by regulatory authorities,
such as the FDA and investigational review boards, whether
favorable or unfavorable; the Company’s ability to obtain, maintain
and enforce necessary patent and other intellectual property
protection; the nature of competition and development relating to
COVID-19 immunization and therapeutic treatments; other potential
adverse impacts due to the global COVID-19 pandemic, such as delays
in regulatory review, interruptions to manufacturers and supply
chains, adverse impacts on healthcare systems and disruption of the
global economy; and general economic and market conditions risks,
as well as other uncertainties described in our filings with the
U.S. Securities and Exchange Commission. Oragenics assumes no
responsibility to update any forward-looking statements contained
in this press release or with respect to the matters described
herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200911005120/en/
Oragenics: Michael Sullivan Chief Financial Officer
813-286-7900 msullivan@oragenics.com Investors: John Marco
Managing Director CORE IR 516-222-2560 johnm@coreir.com
Media: Jules Abraham CORE IR 917-885-7378
julesa@coreir.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024